Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

51 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase I and pharmacokinetic study of LU79553, a DNA intercalating bisnaphthalimide, in patients with solid malignancies.
Villalona-Calero MA, Eder JP, Toppmeyer DL, Allen LF, Fram R, Velagapudi R, Myers M, Amato A, Kagen-Hallet K, Razvillas B, Kufe DW, Von Hoff DD, Rowinsky EK. Villalona-Calero MA, et al. Among authors: velagapudi r. J Clin Oncol. 2001 Feb 1;19(3):857-69. doi: 10.1200/JCO.2001.19.3.857. J Clin Oncol. 2001. PMID: 11157040 Clinical Trial.
Phase I and pharmacokinetic study of the water-soluble dolastatin 15 analog LU103793 in patients with advanced solid malignancies.
Villalona-Calero MA, Baker SD, Hammond L, Aylesworth C, Eckhardt SG, Kraynak M, Fram R, Fischkoff S, Velagapudi R, Toppmeyer D, Razvillas B, Jakimowicz K, Von Hoff DD, Rowinsky E. Villalona-Calero MA, et al. Among authors: velagapudi r. J Clin Oncol. 1998 Aug;16(8):2770-9. doi: 10.1200/JCO.1998.16.8.2770. J Clin Oncol. 1998. PMID: 9704730 Clinical Trial.
Clinical and pharmacologic phase I study of Cemadotin-HCl (LU103793), a novel antimitotic peptide, given as 24-hour infusion in patients with advanced cancer. A study of the Arbeitsgemeinschaft Internistische Onkologie (AIO) Phase I Group and Arbeitsgruppe Pharmakologie in der Onkologie und Haematologie (APOH) Group of the German Cancer Society.
Mross K, Berdel WE, Fiebig HH, Velagapudi R, von Broen IM, Unger C. Mross K, et al. Among authors: velagapudi r. Ann Oncol. 1998 Dec;9(12):1323-30. doi: 10.1023/a:1008430515881. Ann Oncol. 1998. PMID: 9932163 Free article. Clinical Trial.
Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study.
Weisman MH, Moreland LW, Furst DE, Weinblatt ME, Keystone EC, Paulus HE, Teoh LS, Velagapudi RB, Noertersheuser PA, Granneman GR, Fischkoff SA, Chartash EK. Weisman MH, et al. Clin Ther. 2003 Jun;25(6):1700-21. doi: 10.1016/s0149-2918(03)80164-9. Clin Ther. 2003. PMID: 12860493 Clinical Trial.
The effect of food and antacid on the absorption of fendosal.
Wills RJ, Velagapudi RB, Puri SK, Yakatan GJ. Wills RJ, et al. Among authors: velagapudi rb. Biopharm Drug Dispos. 1985 Jan-Mar;6(1):43-50. doi: 10.1002/bdd.2510060106. Biopharm Drug Dispos. 1985. PMID: 3872688 Clinical Trial.
51 results